SCHEMBL1563393

SCHEMBL1563393

C[C@@H]([NH])C(C)(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL786638 1.00
SCHEMBL1564391 1.00
SCHEMBL271370 0.73
SCHEMBL2426770 0.73
SCHEMBL2430204 0.73
SCHEMBL22975 0.73
SCHEMBL16786320 0.72
SCHEMBL1245043 0.72
SCHEMBL4127007 0.72
SCHEMBL9921667 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1628968-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS MITSUBISHI TANABE PHARMA CORP (JP) 2011-04-06 EP claimed
US-7449474-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-11-11 US claimed
EP-1747204-B1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS PROCTER & GAMBLE (US) 2008-07-30 EP claimed
EP-1747204-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS The Procter and Gamble Company (US) 2007-01-31 EP claimed
WO-2005105758-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-11-10 WO claimed
US-20050239811-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-10-27 US claimed
EP-1628968-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS MITSUBISHI TANABE PHARMA CORP (JP) 2011-04-06 EP disclosed